Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization
Advanced Science · 2025
DOI: 10.1002/advs.202408992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jinlin Miao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology of Xijing Hospital and Department of Cell Biology of National Translational Science Center for Molecular Medicine, …. Hauptthemen laut MEDLINE: Artesunate, Macrophages, Interferon Regulatory Factors, Neointima. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Vascular restenosis is a serious clinical issue initiated and aggravated by macrophage inflammation, with no effective treatments available, in cardiovascular and autoimmune diseases. However, the untapped mechanisms and new targets that can regulate macrophage polarization and vascular restenosis remain elusive. The research identifies interferon regulatory factor 4 (IRF4) expression as crucial in macrophage polarization during arterial restenosis. Myeloid‐specific Irf4 deficiency and overexpression experiments showed that IRF4 promoted M2 macrophage polarization, inhibited M1 macrophage transitions, and disrupted the interaction between macrophages and vascular smooth muscle cells to reduce neointimal hyperplasia by directly upregulating krüppel like factor 4 (KLF4) expression. Artesunate, an FDA‐approved drug, is screened as a potent activator of IRF4 expression in M2 polarization, and its treatment attenuated arterial restenosis in rodents and non‐human primates. The findings reveal a significant protective role of IRF4 in the development of neointimal hyperplasia by regulating macrophage polarization, and artesunate may be proposed as a novel therapy for vascular restenosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology of Xijing Hospital and Department of Cell Biology of National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, 710032, China.
- Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, 430060, China.
- Institute of Model Animal, Wuhan University, Wuhan, 430071, China.
- School of Basic Medical Science, Wuhan University, Wuhan, 430071, China.
- Department of Geriatrics, Zhongnan Hospital, Wuhan University, Wuhan, 430070, China.
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
ORCID-Profile: Ping Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Miao, J., Yong, Y., Zheng, Z., Zhang, K., Li, W., Liu, J., Zhou, S., Qin, J. J., Sun, H., Wang, Y., Fu, X., Luo, X., Chen, S., She, Z. G., Cai, J., & Zhu, P. (2025). Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization. Advanced Science. https://doi.org/10.1002/advs.202408992
Vancouver
Miao J, Yong Y, Zheng Z, Zhang K, Li W, Liu J, et al. Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization. Advanced Science. 2025. doi:10.1002/advs.202408992
BibTeX
@article{Miao2025,
author = {Miao, Jinlin and Yong, Yule and Zheng, Zhaohui and Zhang, Kui and Li, Wei and Liu, Jiayi and Zhou, Siyi and Qin, Juan-Juan and Sun, Haoyang and Wang, Yatao and Fu, Xianghui and Luo, Xing and Chen, Siyu and She, Zhi-Gang and Cai, Jingjing and Zhu, Ping},
title = {Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202408992}
}
EUVIMED